Repatha Pushtronex. Amgen's Repatha approved for singledose delivery option in Europe Read and carefully follow all instructions for using this product Alternative presentations are available, and Amgen has sufficient product to meet the demand of patients transitioning from the Pushtronex ® system.
Repatha® Demonstration Kit Structural Graphics from www.structuralgraphics.com
If you are currently using the Repatha ® Pushtronex ® system, we kindly advise you to consult with your healthcare provider and transition to one of the other approved Repatha ® devices, preferably the SureClick. The Repatha ® SureClick ® Autoinjector is still active and available and will be appropriate for.
Repatha® Demonstration Kit Structural Graphics
• Repatha® Pushtronex® System is discontinued, to be followed by the discontinuation of the prefilled syringe mid-2025 Amgen ® has made the decision to discontinue the Repatha ® Pushtronex ® System • Repatha® Pushtronex® System is discontinued, to be followed by the discontinuation of the prefilled syringe mid-2025
Amgen's Repatha approved for singledose delivery option in Europe. 1 † Patients who reported 2 full-dose administrations of Repatha ® at. Alternative presentations are available, and Amgen has sufficient product to meet the demand of patients transitioning from the Pushtronex ® system.
Repatha 140mg Injection Speciality Drugs. The Repatha ® Co-pay Card may modify the benefit amount, unilaterally determined by Amgen in its sole discretion, to satisfy the out-of-pocket cost-sharing requirement for any patient whose plan or plan agent (including, but not limited to, a Pharmacy Benefit Manager (PBM)) requires enrollment in the Repatha ® Co-pay Card as a condition of. The patient should wait at least 30 minutes for the autoinjector to reach room temperature before injecting